Amphastar Pharma

Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus across all profitability metrics: revenue reached $183.9M (+2.2% vs. $179.9M expected), while normalized EPS of $0.91 outperformed the $0.61 estimate by 49.2%. Despite competitive pricing in Glucagon, the strong launch of Ipratropium Bromide and growth in high-margin products like Iron Sucrose expanded gross margins to 50.8% (vs. 49.1% expected). Management confirmed hitting the $175M annual sales milestone for BAQSIMI®, triggering a $100M payment to Eli Lilly in Q3.